Skip to search formSkip to main contentSkip to account menu

BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315I

Known as: BCR-ABL1 T315I Mutation, BCR-ABL Thr315Ile Mutation, BCR/ABL Fusion Protein with T315I 
A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.944C>T mutation. This protein is comprised of the N-terminus of the… 
National Institutes of Health

Related topics

Related topics

6 relations
BCR-ABL Fusion GeneFusion GeneNeoplastic Cell TransformationOncogenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main…
Patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib with… 
Review
2011
Review
2011
The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis
Hedgehog (Hh) is a developmental signaling pathway in which Hh ligands bind Patched (Ptch), which relieves its inhibition of… 
Highly Cited
2010
Highly Cited
2010
A Novel FRET-Based Biosensor for the Measurement of BCR-ABL Activity and Its Response to Drugs in Living Cells
Purpose: To develop a novel diagnostic method for the assessment of drug efficacy in chronic myeloid leukemia (CML) patients… 
Highly Cited
2009
Highly Cited
2009
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
In imatinib-treated chronic myeloid leukemia (CML), secondary drug resistance is often caused by mutations in the BCR-ABL kinase… 
Review
2008
Review
2008
Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF 2
reaction (PCR) methods as previously described in detail.1,2 Forty-six (1.8%) cases showed an ambiguous result and were not… 
Highly Cited
2007
Highly Cited
2007
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
Residual leukemia is demonstrable by reverse transcriptase-polymerase chain reaction in most patients with chronic myeloid… 
Highly Cited
2007
Highly Cited
2007
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
PURPOSE Intrinsic sensitivity to imatinib, based on measurement of inhibitory concentration 50% for imatinib, is variable in… 
Highly Cited
2006
Highly Cited
2006
The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.
BCR-ABL kinase mutations may confer resistance to imatinib in patients with chronic myeloid leukemia (CML), and may predict a… 
Highly Cited
2005
Highly Cited
2005
Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL
Resistance to imatinib during the treatment of chronic myeloid leukaemia (CML) is frequently associated with point mutations in… 
Highly Cited
2001
Highly Cited
2001
Roots of clinical resistance to STI-571 cancer therapy.
STI-571, a new Abl tyrosine kinase inhibitor recently approved by the Food and Drug Administration, is highly effective in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)